Biotech Manufacturers to Develop Better Nucleic Acid Sample Preparation Protocols
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
Manufacturers of biotech equipment and reagents are cooperating to ease and simplify protocols for preparing samples to be analyzed by advanced next generation sequencing platforms.
The success of techniques such as next-generation sequencing, microarrays, and library construction is contingent upon the precise and accurate processing of DNA and RNA. Library preparation of nucleic acids relies on a coordinated series of standard molecular biology reactions, and preparation of high quality libraries at high yield is a critical first step in the next generation sequencing workflow. The necessity for improved reagents and protocols for library preparation is growing in parallel with the increase in the number of applications for next generation sequencing.
To develop these new protocols, the instrument manufacturer Beckman Coulter Life Sciences (Nyon, Switzerland) will be collaborating with the reagent manufacturer New England Biolabs, Inc. (Ipswich, MA, USA). Beckman Coulter produces advanced automated liquid handling systems such as the Biomek 4000. New England Biolabs manufactures a line of highly pure "NEBNext" reagents that facilitate library preparation of DNA or RNA for downstream applications such as next generation sequencing and expression library construction.
It is planned that Beckman Coulter will use its extensive experience in automated next generation sequencing sample preparation to develop, distribute, and support automation for New England Biolabs' NEBNext sample preparation reagent kits. New England Biolabs will provide technical expertise on the reagents, chemistry, and protocols.
“Beckman Coulter’s focus on providing our next generation sequencing customers a top-notch portfolio of automated sample preparation solutions makes a partnership with New England Biolabs, a world leading provider of quality reagent systems for molecular biology research, a natural fit,” said Alisa Jackson, senior marketing manager, automated genomics solutions at Beckman Coulter. “Our joint collaborations with scientific researchers have already led to the development of high-quality methods demonstrated to improve efficiency, throughput and results for some of the most challenging sample inputs.”
Related Links:
Beckman Coulter Life Sciences
New England Biolabs, Inc.
The success of techniques such as next-generation sequencing, microarrays, and library construction is contingent upon the precise and accurate processing of DNA and RNA. Library preparation of nucleic acids relies on a coordinated series of standard molecular biology reactions, and preparation of high quality libraries at high yield is a critical first step in the next generation sequencing workflow. The necessity for improved reagents and protocols for library preparation is growing in parallel with the increase in the number of applications for next generation sequencing.
To develop these new protocols, the instrument manufacturer Beckman Coulter Life Sciences (Nyon, Switzerland) will be collaborating with the reagent manufacturer New England Biolabs, Inc. (Ipswich, MA, USA). Beckman Coulter produces advanced automated liquid handling systems such as the Biomek 4000. New England Biolabs manufactures a line of highly pure "NEBNext" reagents that facilitate library preparation of DNA or RNA for downstream applications such as next generation sequencing and expression library construction.
It is planned that Beckman Coulter will use its extensive experience in automated next generation sequencing sample preparation to develop, distribute, and support automation for New England Biolabs' NEBNext sample preparation reagent kits. New England Biolabs will provide technical expertise on the reagents, chemistry, and protocols.
“Beckman Coulter’s focus on providing our next generation sequencing customers a top-notch portfolio of automated sample preparation solutions makes a partnership with New England Biolabs, a world leading provider of quality reagent systems for molecular biology research, a natural fit,” said Alisa Jackson, senior marketing manager, automated genomics solutions at Beckman Coulter. “Our joint collaborations with scientific researchers have already led to the development of high-quality methods demonstrated to improve efficiency, throughput and results for some of the most challenging sample inputs.”
Related Links:
Beckman Coulter Life Sciences
New England Biolabs, Inc.
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest BioResearch News
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more









